CONCARLO HOLDINGS, LLC

  • CONCARLO HOLDINGS, LLC

Developing solutions for drug-resistant breast cancer

MORE ABOUT US

About us

TECHNOLOGY

 

Breast cancer remains a significant burden on human health. Almost 250,000 US women will be diagnosed this year and approximately 40,000 women will die. ER/PR+ (endocrine responsive) Her2- tumors occur in approximately 90,000 breast cancer patients each year, of which 20,000 develop drug resistance. For these patients, despite advances in available drugs, the best existing solutions do not provide durable arrest of the tumors. The patient becomes resistant to the drug and overall survival rates are unchanged.

 

Using our patent technologies, we can dramatically increase drug efficacy and diagnostic evaluations for ER/PR+ Her 2- patients. IpY, a cdk inhibitor, specifically addresses drug resistance issues. Concarlo believes that, as a cdk inhibitor, IpY will have efficacy in many different cancers. ApY is an antibody that can be used to pinpoint patients who will respond to cdk4 inhibiting therapies. This built-in biomarker and surrogate endpoint should highlight tumors that would be responsive to this type of therapy, providing clinicians with needed information before treatment is started and as it is progressing.

 

Our Team

News

Women & Wealth Magazine
18 Women to Watch in 2018 

Features Dr. Stacy Blain, Co-Founder and Chief Scientific Officer, Concarlo Holdings





SUNY Downstate Medical Center Press Release

SUNY Downstate Startup Company Secures Over $1 Million in Seed Funding Investment for Advancement of Proprietary Cancer Companion Diagnostic Test





Newsday Business Article

LI venture capital fund invests in NYC biotech startup






Impact Journals: Oncoscience May 2018

Click here to download Stacy’s article:
Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breast cancer cells.





Molecular Cancer Research Journal
March 2018

Click here to download Stacy and Priyank’s article:
Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells






Going Through It Together

Stacy and Catherine’s Grand Canyon Hike






Student Visit from EDsnaps

Increasing diversity in the Science Technology Engineering & Mathematics (STEM) Workforce


Research Associate Sarah Teed, M.S. welcomes young students to learn more about Concarlo’s mission.






Save

Save


  • WRITE US AT

    info@concarlo.com

  • OUR LAB

    Downstate Biotechnology Incubator
    760 Parkside Avenue, Room 208
    Brooklyn, NY 11226

  • REACH US HERE

    347.240.0341


Contact Us